Renexxion Ireland is a Roscrea, Ireland–based private biopharmaceutical company focused on treatments for GI disorders. Its lead program, naronapride, is described as a late‑stage, potential best‑in‑class candidate with combined 5HT4 agonist and D2 antagonist activity and is designed to be minimally absorbable and locally active in the gut lumen. Naronapride has completed four positive Phase II studies and is Phase‑III ready in chronic idiopathic constipation (CIC) and gastro‑esophageal reflux disease (GERD); clinical studies report a side‑effect profile indistinguishable from placebo. The company is also advancing a research program in inflammatory bowel disease (IBD). Renexxion is collaborating with a leading European GI licensing partner to advance naronapride through later development and commercialization in Greater Europe and certain Australasian countries. Financially, the company announced a conditional share subscription commitment intended to fund its lead and additional programs.

Total raised

$100M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2022